Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00117104
Status:
COMPLETED
Last Update Posted:
2009-10-16
First Post:
2005-06-30
Brief Title:
Evaluating Aranesp in Subjects With End Stage Renal Disease onChronic Hemodialysis
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Multicenter Study Evaluating Once Weekly Intravenous Administration of Aranesp in Subjects With End Stage Renal Disease on Chronic Hemodialysis
Status:
COMPLETED
Status Verified Date:
2009-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the Aranesp dose administered intravenously IV once weekly to maintain hemoglobin Hgb levels in hemodialysis subjects who are either recombinant human erythropoietin rHuEPO naïve or subjects converted from rHuEPO therapy administered IV thrice weekly TIW
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None